Karyopharm Therapeutics | KPTI - Gross Profit On Sales


Karyopharm Therapeutics reported $-30.78M in Gross Profit on Sales for its fiscal quarter ending in December of 2024.





Gross Profit On Sales Change Date
AbbVie USD 10.47B 605M Sep/2025
Abbott USD 6.54B 625M Dec/2025
Amgen USD 6.48B 307M Sep/2025
AstraZeneca USD 12.39B 5M Dec/2025
BioCryst Pharmaceuticals USD -88.88M 202.74M Dec/2024
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Enanta Pharmaceuticals -22.29M 23.75M Dec/2024
GlaxoSmithKline GBP 6.18B 106M Dec/2025
Incyte USD 1.39B 118.68M Dec/2025
J&J USD 16.6B 118M Dec/2025
Karyopharm Therapeutics USD -30.78M 1.29M Dec/2024
MacroGenics USD 61.25M 88.71M Sep/2025
Merck USD 13.42B 431M Sep/2025
Nektar Therapeutics USD 13.75M 650K Jun/2024
Novartis USD 10.82B 695M Sep/2025
Novartis USD 10.82B 694M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Sangamo BioSciences -2.39M 1.09M Jun/2024
Takeda JPY 790.55B 262.97B Dec/2025
Tectonic Therapeutic USD 0 0 Mar/2025
TG Therapeutics USD 154.43M 20.81M Dec/2025
Ultragenyx Pharmaceutical USD 178M 46.06M Dec/2025
Xencor USD 21M 22.61M Sep/2025